Pentraxin 3 as a marker of development and severity of stable coronary artery disease

IF 2.5 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Malgorzata Knapp, Monika Gil-Mika, Robert Sawicki, Anna Lisowska, Marcin Kaminski, Bozena Sobkowicz, Katarzyna Ptaszynska
{"title":"Pentraxin 3 as a marker of development and severity of stable coronary artery disease","authors":"Malgorzata Knapp,&nbsp;Monika Gil-Mika,&nbsp;Robert Sawicki,&nbsp;Anna Lisowska,&nbsp;Marcin Kaminski,&nbsp;Bozena Sobkowicz,&nbsp;Katarzyna Ptaszynska","doi":"10.1016/j.advms.2024.07.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Inflammation plays a crucial role in the development of atherosclerotic plaques. Pentraxin 3 (PTX3) is produced at the site of inflammation and has been identified as a specific marker of atherosclerosis, vascular inflammation, and progression of the coronary artery disease (CAD).</p><p>The aim of the study was to establish if PTX3 has potential relations with classical markers of cardiovascular risk, and if PTX3 may act as an independent risk factor of CAD occurrence and advancement.</p></div><div><h3>Materials and methods</h3><p>The study included 98 patients with stable CAD confirmed in coronary angiography (CAD group) (median age 65 interquartile range [IQR] 61–72 years; 72 ​% men). The control group consisted of 40 patients without CAD.</p></div><div><h3>Results</h3><p>The CAD group had significantly higher PTX3 concentration compared to the control group. There was a correlation with age, male gender, lipid profile and intima-media thickness. There was no correlation between PTX3 concentration and the number of coronary vessels with significant atherosclerotic lesions and the advancement of atherosclerotic lesions on the Gensini scoring scale. The cut-off point was determined for 0.89 ​ng/ml for the exclusion of angiographically significant atherosclerotic lesions.</p></div><div><h3>Conclusions</h3><p>Patients with CAD have significantly higher concentration of PTX3. There was no correlation between PTX3 and the advancement of angiographically significant atherosclerotic lesions in coronary arteries. Low PTX3 concentration may serve as an indicator for the absence of atherosclerosis.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"69 2","pages":"Pages 391-397"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112624000440","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Inflammation plays a crucial role in the development of atherosclerotic plaques. Pentraxin 3 (PTX3) is produced at the site of inflammation and has been identified as a specific marker of atherosclerosis, vascular inflammation, and progression of the coronary artery disease (CAD).

The aim of the study was to establish if PTX3 has potential relations with classical markers of cardiovascular risk, and if PTX3 may act as an independent risk factor of CAD occurrence and advancement.

Materials and methods

The study included 98 patients with stable CAD confirmed in coronary angiography (CAD group) (median age 65 interquartile range [IQR] 61–72 years; 72 ​% men). The control group consisted of 40 patients without CAD.

Results

The CAD group had significantly higher PTX3 concentration compared to the control group. There was a correlation with age, male gender, lipid profile and intima-media thickness. There was no correlation between PTX3 concentration and the number of coronary vessels with significant atherosclerotic lesions and the advancement of atherosclerotic lesions on the Gensini scoring scale. The cut-off point was determined for 0.89 ​ng/ml for the exclusion of angiographically significant atherosclerotic lesions.

Conclusions

Patients with CAD have significantly higher concentration of PTX3. There was no correlation between PTX3 and the advancement of angiographically significant atherosclerotic lesions in coronary arteries. Low PTX3 concentration may serve as an indicator for the absence of atherosclerosis.

作为稳定型冠状动脉疾病发展和严重程度标志物的五胜肽 3。
目的:炎症在动脉粥样硬化斑块的形成过程中起着至关重要的作用。五胜肽 3(PTX3)产生于炎症部位,已被确定为动脉粥样硬化、血管炎症和冠状动脉疾病(CAD)进展的特异性标志物。该研究的目的是确定 PTX3 是否与心血管风险的经典标志物有潜在的关系,以及 PTX3 是否可能成为 CAD 发生和发展的独立风险因素:研究对象包括98名经冠状动脉造影证实患有稳定型CAD的患者(CAD组)(中位年龄65岁,四分位数区间[IQR]61-72岁;72%为男性)。对照组由 40 名无 CAD 患者组成:结果:与对照组相比,CAD 组的 PTX3 浓度明显更高。PTX3浓度与年龄、男性性别、血脂状况和血管内膜厚度相关。PTX3 浓度与有明显动脉粥样硬化病变的冠状动脉血管数量以及根西尼评分表中动脉粥样硬化病变的进展之间没有相关性。结论:CAD患者体内的PTX3浓度明显高于正常人:结论:CAD 患者的 PTX3 浓度明显更高。结论:冠状动脉粥样硬化患者的 PTX3 浓度明显较高,PTX3 与冠状动脉血管造影显着动脉粥样硬化病变的进展之间没有相关性。PTX3的低浓度可作为没有动脉粥样硬化的指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in medical sciences
Advances in medical sciences 医学-医学:研究与实验
CiteScore
5.00
自引率
0.00%
发文量
53
审稿时长
25 days
期刊介绍: Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信